Multimodal Cancer Foundation Model: A New Tool for Tumor Microenvironment Discovery and Immunotherapy Prediction

multimodal-cancer-foundation-models is an open-source multimodal foundation model project focusing on tumor microenvironment (TME) discovery and immunotherapy prediction. This project integrates pathological images, genomics, and clinical data to provide AI-driven analytical tools for cancer research and precision medicine, helping researchers and clinicians understand tumor biological characteristics and predict immunotherapy responses.

Cancer is the second leading cause of death globally. Traditional research and treatment face many challenges: significant tumor heterogeneity, incomplete understanding of microenvironment mechanisms, low immunotherapy response rates (only 20-30% for some cancer types), and difficulties in integrating multi-source data. In recent years, foundation models have shown potential in the medical field, bringing new hope to cancer research.

The core objectives of the project are TME discovery and immunotherapy prediction. Core capabilities include:

1. Tumor microenvironment analysis: Identify and quantify immune cells such as TILs and TAMs
2. Immunotherapy response prediction: Predict PD-1/PD-L1 inhibitor responses based on multimodal data
3. Spatial transcriptome integration: Combine pathological spatial information with gene expression
4. Biomarker discovery: Identify molecular features related to prognosis and treatment response

The project is maintained by ag48665 and released on GitHub (link: https://github.com/ag48665/multimodal-cancer-foundation-models) on May 28, 2026.

The technical architecture adopts multimodal fusion and foundation model paradigms:

• Multimodal data fusion: Pathological image encoders (ViT/UNI/HIPT), genomics encoders (processing gene expression/mutations/copy number variations), clinical data encoders (integrating age/gender/stage, etc.), and cross-modal attention mechanisms to achieve feature alignment
• Foundation model paradigm: Large-scale pre-training (self-supervised on massive unlabeled data) → domain adaptation (fine-tuning for specific cancer types) → task fine-tuning (supervised fine-tuning for downstream tasks), learning general cancer biological representations

Application scenarios cover three major areas: Research applications: Tumor immunology research (composition and distribution of immune cells in TME), treatment mechanism exploration, new target discovery Clinical applications: Treatment decision support (predicting immunotherapy responses), prognosis assessment, clinical trial patient screening Drug development: Companion diagnostic development, clinical trial design optimization, drug repurposing

The project addresses three major technical challenges:

1. Data heterogeneity: Domain adaptation to reduce cross-center differences, standardized preprocessing, multi-center pre-training to enhance robustness
2. Scarce annotations: Self-supervised learning on unlabeled data, semi-supervised use of small amounts of annotations, active learning to prioritize labeling high-value data
3. Interpretability: Attention visualization to highlight image regions, feature importance analysis, natural language reports to explain decisions

Summary: This project represents the cutting-edge application of AI in cancer research. Through multimodal data and foundation model technology, it provides a powerful tool for TME research and immunotherapy prediction, accelerating the development of precision medicine.

Future directions include: expanding to more cancer types, optimizing real-time analysis capabilities, supporting federated learning, and conducting clinical validation studies.

In terms of ethics and privacy, the project strictly desensitizes data, assesses fairness, provides transparency, and complies with regulatory requirements.